Title: Inducible CRISPR/Cas9 Systems in the Treatment of Neurodegenerative Diseases
Abstract:Inducible clustered, regularly interspaced, short, palindromic repeats with the CRISPR-associated protein 9 (CRISPR/Cas9) system are a legitimate avenue for treating Parkinson’s and Huntington’s disea...Inducible clustered, regularly interspaced, short, palindromic repeats with the CRISPR-associated protein 9 (CRISPR/Cas9) system are a legitimate avenue for treating Parkinson’s and Huntington’s diseases. The CRISPR/Cas9 system, introduced in 2012, is a breakthrough gene-editing mechanism that can be used to modify genomes. The CRISPR/Cas9 system has been used to treat neurodegenerative diseases such as Parkinson’s and Huntington’s. Until now, a majority of CRISPR/Cas9 approaches have been geared towards treating the symptoms of these diseases rather than the causes themselves. Drug inducible CRISPR/Cas9 systems provide more avenues for novel treatments of Parkinson's and Huntington’s diseases that target the genetic causes of these diseases rather than the symptoms. Although there are many limitations to CRISPR, such as delivery methods and target specificity, many improvements are being implemented to increase the efficiency and efficacy of the CRISPR/Cas9 system.Read More